{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:58:46Z","timestamp":1740124726727,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T00:00:00Z","timestamp":1650067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T00:00:00Z","timestamp":1650067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1038\/s41409-022-01679-6","type":"journal-article","created":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T13:03:43Z","timestamp":1650114223000},"page":"1034-1037","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Venetoclax-based regimens in combination with trametinib for RAS-mutated relapsed or refractory myeloid malignancies"],"prefix":"10.1038","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3536-3701","authenticated-orcid":false,"given":"Lukas","family":"Kevlicius","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruta","family":"Cepulyte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominika","family":"Vasilevska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laimonas","family":"Griskevicius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5520-1534","authenticated-orcid":false,"given":"Andrius","family":"Zucenka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,16]]},"reference":[{"key":"1679_CR1","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135:791\u2013803.","journal-title":"Blood."},{"key":"1679_CR2","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1038\/s41409-021-01416-5","volume":"56","author":"A Zucenka","year":"2021","unstructured":"Zucenka A, Vaitekenaite V, Maneikis K, Davainis L, Pileckyte R, Trociukas I, et al. Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2021;56:2804\u201312.","journal-title":"Bone Marrow Transplant"},{"key":"1679_CR3","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3324\/haematol.2020.252569","volume":"106","author":"A Maiti","year":"2020","unstructured":"Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, et al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2020;106:894\u20138.","journal-title":"Haematologica."},{"key":"1679_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/ejh.13527","volume":"106","author":"A Zucenka","year":"2021","unstructured":"Zucenka A, Pileckyte R, Trociukas I, Peceliunas V, Vaitekenaite V, Maneikis K, et al. Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax\u2010based salvage therapies. Eur J Haematol. 2021;106:105\u201313.","journal-title":"Eur J Haematol"},{"key":"1679_CR5","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","volume":"1","author":"H Zhang","year":"2020","unstructured":"Zhang H, Nakauchi Y, K\u00f6hnke T, Stafford M, Bottomly D, Thomas R, et al. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat Cancer. 2020;1:826\u201339.","journal-title":"Nat Cancer"},{"key":"1679_CR6","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","volume":"5","author":"M Stahl","year":"2021","unstructured":"Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML. Blood Adv. 2021;5:1552\u201364.","journal-title":"Blood Adv"},{"key":"1679_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41571-018-0105-0","volume":"15","author":"MB Ryan","year":"2018","unstructured":"Ryan MB, Corcoran RB. Therapeutic strategies to target RAS-mutant cancers. Nat Rev Clin Oncol. 2018;15:709\u201320.","journal-title":"Nat Rev Clin Oncol"},{"key":"1679_CR8","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3324\/haematol.2018.205534","volume":"105","author":"L Han","year":"2020","unstructured":"Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, et al. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica. 2020;105:697\u2013707.","journal-title":"Haematologica."},{"key":"1679_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.clml.2018.12.009","volume":"19","author":"A Maiti","year":"2019","unstructured":"Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, et al. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2019;19:142\u20138.e1.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1679_CR10","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.clml.2019.03.015","volume":"19","author":"BK Ragon","year":"2019","unstructured":"Ragon BK, Odenike O, Baer MR, Stock W, Borthakur G, Patel K, et al. Oral MEK 1\/2 inhibitor trametinib in combination with AKT inhibitor GSK2141795 in patients with acute myeloid leukemia with RAS mutations: a phase II study. Clin Lymphoma Myeloma Leuk. 2019;19:431\u201340.e13","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1679_CR11","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1002\/cncr.29986","volume":"122","author":"G Borthakur","year":"2016","unstructured":"Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, et al. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies: trametinib in RAS-mutant malignancies. Cancer. 2016;122:1871\u20139.","journal-title":"Cancer."},{"key":"1679_CR12","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1158\/1538-7445.AM2021-1429","volume":"81","author":"A Damnernsawad","year":"2021","unstructured":"Damnernsawad A, Eide CA, Beer S, Zhang H, Bottomly D, Kurtz SE, et al. Abstract 1429: characterization of trametinib combined with venetoclax in acute myeloid leukemia (AML) treatment. Cancer Res. 2021;81 13 Supplement:1429.","journal-title":"Cancer Res"},{"issue":"Supplement 1","key":"1679_CR13","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1182\/blood.V130.Suppl_1.813.813","volume":"130","author":"N Daver","year":"2017","unstructured":"Daver N, Pollyea DA, Yee KWL, Fenaux P, Brandwein JM, Vey N, et al. Preliminary results from a phase Ib study evaluating BCL-2 inhibitor venetoclax in combination with MEK inhibitor cobimetinib or MDM2 inhibitor idasanutlin in patients with relapsed or refractory (R\/R) AML. Blood 2017;130 Supplement 1:813.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1679_CR14","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.1182\/blood-2021-151707","volume":"138","author":"SP Desikan","year":"2021","unstructured":"Desikan SP, Ravandi F, Pemmaraju N, Konopleva M, Loghavi S, Borthakur G, et al. A phase II study of azacitidine, venetoclax and trametinib in relapsed\/refractory AML harboring a Ras pathway-activating mutation. Blood 2021;138 Supplement 1:4436.","journal-title":"Blood"},{"key":"1679_CR15","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1182\/blood-2021-144434","volume":"138","author":"A Zucenka","year":"2021","unstructured":"Zucenka A, Vaitek\u0117nait\u0117 V, Maneikis K, Pileckyt\u0117 R, Trociukas I, Pe\u010deli\u016bnas V, et al. Venetoclax, actinomycin D and low dose cytarabine for relapsed or refractory acute myeloid leukemia in clinical practice setting. Blood. 2021;138 Supplement 1:3422.","journal-title":"Blood."}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01679-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01679-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01679-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T16:07:12Z","timestamp":1655309232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01679-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,16]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1679"],"URL":"https:\/\/doi.org\/10.1038\/s41409-022-01679-6","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"type":"print","value":"0268-3369"},{"type":"electronic","value":"1476-5365"}],"subject":[],"published":{"date-parts":[[2022,4,16]]},"assertion":[{"value":"7 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LK: None. RC: None. DV: None. LG: <i>AbbVie<\/i>\u2014travel expenses. AZ: <i>Jannsen<\/i>\u2014honoraria, travel expenses; <i>Takeda<\/i>\u2014travel expenses; <i>Novartis<\/i>\u2014honoraria, travel expenses; <i>Pfizer<\/i>\u2014honoraria, travel expenses; <i>Astellas<\/i>\u2014honoraria; <i>AbbVie<\/i>\u2014honoraria, travel expenses.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The data collection was approved by Vilnius Regional Biomedical Research Ethics Committee (rbtek@mf.vu.lt, approval No. 2019\/2-1088-591) and the study was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients for being included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}